ALXN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Alexion Pharmaceuticals Inc's research and development for the three months ended in Mar. 2016 was $176 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2016 was $665 Mil.
This is the expense the company spent on research and development.
Alexion Pharmaceuticals Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2016 was 131.693 (Jun. 2015 ) + 165.664 (Sep. 2015 ) + 191.035 (Dec. 2015 ) + 176.29 (Mar. 2016 ) = $665 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Alexion Pharmaceuticals Inc Annual Data
|Research & Development||83||69||63||82||98||137||223||317||514||709|
Alexion Pharmaceuticals Inc Quarterly Data
|Research & Development||86||191||93||101||129||221||132||166||191||176|